These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 18515176)

  • 1. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
    Erman M
    J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology.
    Bertolini F
    Breast; 2009 Oct; 18 Suppl 3():S48-50. PubMed ID: 19914542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular predictors of response to chemotherapy in colorectal cancer.
    Dienstmann R; Vilar E; Tabernero J
    Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor receptors: expression and function in solid tumors.
    Wey JS; Stoeltzing O; Ellis LM
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
    Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
    Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.
    Baron AT; Wilken JA; Haggstrom DE; Goodrich ST; Maihle NJ
    IDrugs; 2009 May; 12(5):302-8. PubMed ID: 19431095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and cellular biomarkers for angiogenesis in clinical oncology.
    Bertolini F; Mancuso P; Shaked Y; Kerbel RS
    Drug Discov Today; 2007 Oct; 12(19-20):806-12. PubMed ID: 17933680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting angiogenesis in head and neck cancer.
    Seiwert TY; Cohen EE
    Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in cancer chemotherapy with special stress on molecular-targeted therapy.
    Saijo N
    Jpn J Clin Oncol; 2010 Sep; 40(9):855-62. PubMed ID: 20651047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor.
    Camp ER; Summy J; Bauer TW; Liu W; Gallick GE; Ellis LM
    Clin Cancer Res; 2005 Jan; 11(1):397-405. PubMed ID: 15671571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
    Gilbert JA; Adhikari LJ; Lloyd RV; Rubin J; Haluska P; Carboni JM; Gottardis MM; Ames MM
    Endocr Relat Cancer; 2010 Sep; 17(3):623-36. PubMed ID: 20385747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials.
    Krause M; Baumann M
    Cancer Metastasis Rev; 2008 Sep; 27(3):387-402. PubMed ID: 18427731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy.
    Riesterer O; Milas L; Ang KK
    J Clin Oncol; 2007 Sep; 25(26):4075-83. PubMed ID: 17827456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future.
    Taylor M; Rössler J; Geoerger B; Vassal G; Farace F
    Expert Opin Investig Drugs; 2010 Jul; 19(7):859-74. PubMed ID: 20470190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer.
    Rohrberg KS; Skov BG; Lassen U; Christensen IJ; Høyer-Hansen G; Buysschaert I; Pappot H
    Cancer Biomark; 2010; 7(3):141-51. PubMed ID: 21263190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.